Do you offer somatostatin analogues (eg lanreotide, octreotide) to asymptomatic patients with metastatic, nonfunctioning, well-differentiated enteropancreatic neuroendrocrine tumors?

I do use SSA in non-functional NET because of the clear PFS benefit observed. There is a difference between whether a drug may have OS benefit in a particular setting vs whether it is possible to demonstrate it in a clinical trial. Please see our position paper:

Future directions in the treatment of ...